

Acute Gastroenteritis*	
Presentation	Diarrhea (3+ loose/watery stools per day), vomiting, fever, anorexia, cramping. Common, 2 episodes/year on avg in children < 5.
Pathophys	<ul style="list-style-type: none"> • Viruses (rotavirus, norovirus, enteric adenovirus, calicivirus, astrovirus, enterovirus) are major cause → low-grade fever, vomiting, watery diarrhea WITHOUT blood. • Bacteria (SSYCE +C.Diff) cause infiltration of mucosal lining → fever, abdominal pain, bloody stools, positive stool leukocytes • Parasitic (<i>Giardia</i>, <i>Cryptosporidia</i>, <i>Cyclospora</i>, <i>E. histolytica</i>)
Treatment	<ul style="list-style-type: none"> • Dehydration score determines management. If severe, obtain POC BG + lytes and start IVF. • Otherwise, oral rehydration solution, e.g. Pedialyte or ½ strength apple juice (theoretical risk that high osmolality fluids will worsen diarrhea and hypoNa fluids will lead to hypoNa, but one RCT demonstrated improved outcomes w/ ½ strength apple juice b/c Pedialyte = not tasty.) No evidence for bowel rest or bland diet.

Infectious Hepatitis	
Hepatitis A	
Transmission	Fecal-oral, blood
Epi	High in Mexico, S. America, Africa, Asia
Incubat	2-8 wks
Prophylaxis	HepA Vaccine. pre- / post-exposure with polyclonal IgG
Treatment	<ul style="list-style-type: none"> • Supportive • Vit K for coagulopathy
Prognosis	Usually self-limiting
Hepatitis B	
Transmission	Blood, sex, maternal-fetal (90% vertical transmission rate, but infants almost always become chronic carriers ; OK to breastfeed)
Epi	<ul style="list-style-type: none"> • 1-2% in US • Higher in Asia and South America • 10-20% in China, sub-Saharan Africa
Incubat	1-4 mo
Prophylaxis	Post-exposure with HBIG and HBV vaccine within 12 hours (newborns born to HBV+, needlesticks)
Treatment	<ul style="list-style-type: none"> • Entecavir • Tenofovir • Peginterferon alfa-2a • IFNa: 20-50% will seroconvert, but lots of systemic side effects • Lamivudine: high rate of resistance
Prognosis	<ul style="list-style-type: none"> • Self-limited or progression to chronic HBV/carrier status (esp. neonates) • Cirrhosis in 3% • Increased risk of hepatocellular CA (yearly RUQ ultrasound, AFP level)
Serologies	<ul style="list-style-type: none"> • HBsAg (surface antigen): indicative of acute infection, disappears in 3-6 months • HBsAg for >6 months: carrier state • HBeAg (secretory protein) and HBV DNA by PCR suggest active viral replication • IgM anti-HBc (antibody to core protein): secondary indicator of acute infection • HBsAb (antibody to surface protein): neutralizing antibody, suggests recovery or response to HBV vaccine